This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Atkins MB , Plimack ER , Puzanov I , Fishman MN , McDermott DF , Cho DC , Vaishampayan U , George S , Tarazi JC , Duggan W , Perini R , Thakur M , Fernandez KC , Choueiri TK
Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial
Eur J Cancer. 2021 Mar;145 :1-10
PMID: 33412465 URL: https://www.ncbi.nlm.nih.gov/pubmed/33412465
AbstractBACKGROUND: Axitinib plus pembrolizumab showed superior overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) versus sunitinib in a randomised phase III trial in patients with advanced renal-cell carcinoma (RCC). We report long-term efficacy and safety of the axitinib/pembrolizumab from the phase I trial (NCT02133742), after 46-55 months from study initiation (data cut-off date, 23rd July 2019). METHODS: Fifty-two treatment-naïve patients with advanced RCC were treated with oral axitinib 5 mg twice daily and intravenous pembrolizumab 2 mg/kg every 3 weeks. PFS, duration of response (DoR) and OS were summarised using the Kaplan-Meier method. RESULTS: At a median follow-up of 42.7 months (95% confidence interval [CI]: 41.1-44.1), median OS was not reached; 38 (73.1%) patients were alive. The probability of being alive at 4 years was 66.8% (95% CI: 49.1-79.5). Median PFS in the overall population was 23.5 months (95% CI: 15.4-30.4). ORR was 73.1%; five patients had complete response. Median DoR was 22.1 months (95% CI: 15.1-34.5). Grade III/IV adverse events (AEs) were reported in 38 (73.1%) patients and 20 (38.5%) discontinued treatment because of AEs: 17 (32.7%) discontinued axitinib, 13 (25.0%) discontinued pembrolizumab, and 10 (19.2%) discontinued both drugs. Common AEs included diarrhoea (84.6%), fatigue (80.8%), hypertension (53.8%), cough (48.1%) and dysphonia (48.1%). There were no new AE terms reported and no treatment-related deaths. CONCLUSIONS: In patients with advanced RCC with ~4 years of follow-up, combination axitinib/pembrolizumab continued to demonstrate clinical benefit, with no new safety signals.
Notes1879-0852 Atkins, Michael B Plimack, Elizabeth R Puzanov, Igor Fishman, Mayer N McDermott, David F Cho, Daniel C Vaishampayan, Ulka George, Saby Tarazi, Jamal C Duggan, William Perini, Rodolfo Thakur, Mahgull Fernandez, Kathrine C Choueiri, Toni K Journal Article England Eur J Cancer. 2021 Jan 4;145:1-10. doi: 10.1016/j.ejca.2020.12.009.